drugset / Trial / NCT00320567
The Effect of Norgestimate/Ethinyl Estradiol on Bone Density in Pediatric Subjects With Anorexia Nervosa
Phase 2
Completed
123 enrolled
McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the effect of norgestimate/ethinyl estradiol on lumbar spine (L1-L4) and total hip bone mineral density (BMD) in pediatric subjects with anorexia nervosa.
Timeline
- Start
- —
- Primary completion
- —
- Completion
- 2004-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Norgestimate | Small molecule | 0.18 mg | Oral |
| Subject | Norgestimate | Small molecule | 0.215 mg | Oral |
| Subject | Norgestimate | Small molecule | 0.25 mg | Oral |
| Subject | ethinyl estradiol | Small molecule | 0.035 mg | Oral |